human papillomavirus 16 monovalent Report issue

Vaccine Experimental
AACT MeSH

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

e7 oncoprotein, human papilloma virus type-16 | e7 protein, hpv16 | e7 protein, hpv-16 | hpv-16 e6 peptide | hpv-16 e6 peptides | hpv 16 e7:12-20 | hpv-16 e7 peptide | hpv 16 l1 vaccine | hpv-16 vaccine | hpv e7 peptides | human papillomavirus 16 monovalent | oncogene protein e7, human papillomavirus type 16

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Alphapapillomavirus (Phase 1)

Condylomata Acuminata (Phase 3)

Healthy Volunteers (Phase 1)

HIV (Phase 1/Phase 2)

Human papillomavirus 16 (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 1/Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue